Martin LindstrÖm
BOARD MEMBER
immunology
immunicum
Sweden
Biography
Martin Lindström, M.Sc., represents the principal owner Loggen Invest AB. He has, since 2008, shown great commitment in working so that Immunicum’s products will reach cancer patients and has contributed to the Company with expertise in economics and law, and by his genuine interest in Immunicum’s business. Independence: Martin is independent from the Company and its management but not independent from its primary shareholders. Member of the Board since 2008.
Research Interest
immunology
